Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver
Open Access
- 22 July 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 9 (1), 10596
- https://doi.org/10.1038/s41598-019-46664-0
Abstract
Despite advances in antiviral therapy, molecular drivers of Hepatitis C Virus (HCV)-related liver disease remain poorly characterised. Chronic infection with HCV genotypes (1 and 3) differ in presentation of liver steatosis and virological response to therapies, both to interferon and direct acting antivirals. To understand what drives these clinically important differences, liver expression profiles of patients with HCV Genotype 1 or 3 infection (n = 26 and 33), alcoholic liver disease (n = 8), and no liver disease (n = 10) were analysed using transcriptome-wide microarrays. In progressive liver disease, HCV genotype was the major contributor to altered liver gene expression with 2151 genes differentially expressed >1.5-fold between HCV Genotype 1 and 3. In contrast, only 6 genes were altered between the HCV genotypes in advanced liver disease. Induction of lipogenic, lipolytic, and interferon stimulated gene pathways were enriched in Genotype 1 injury whilst a broad range of immune-associated pathways were associated with Genotype 3 injury. The results are consistent with greater lipid turnover in HCV Genotype 1 patients. Moreover, the lower activity in inflammatory pathways associated with HCV genotype 1 is consistent with relative resistance to interferon-based therapy. This data provides a molecular framework to explain the clinical manifestations of HCV-associated liver disease.Funding Information
- University of Sydney
- Cancer Institute NSW
- Australian Centre for HIV and Hepatitis Virology Research
- Deutsches Zentrum für Infektionsforschung
- Deutsche Forschungsgemeinschaft
This publication has 51 references indexed in Scilit:
- Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategiesLipids in Health and Disease, 2013
- Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3Journal of Viral Hepatitis, 2013
- BeadArray Expression Analysis Using BioconductorPLoS Computational Biology, 2011
- Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 InfectionsGastroenterology, 2011
- Hepatic Hepatocyte Nuclear Factor 4α Is Essential for Maintaining Triglyceride and Cholesterol HomeostasisArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Hepatitis C virus infection and its clearance alter circulating lipids: Implications for long-term follow-upJournal of Hepatology, 2009
- Interferon signaling and treatment outcome in chronic hepatitis CProceedings of the National Academy of Sciences of the United States of America, 2008
- Metric for Measuring the Effectiveness of Clustering of DNA Microarray ExpressionBMC Bioinformatics, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001
- Classification of chronic viral hepatitis: a need for reassessmentJournal of Hepatology, 1991